Safety and efficacy of Atorvastatin-induced very low-density lipoprotein cholesterol levels in Patients with coronary heart disease (a post hoc analysis of the treating to new targets [TNT] study)
- PMID: 17719314
- DOI: 10.1016/j.amjcard.2007.03.102
Safety and efficacy of Atorvastatin-induced very low-density lipoprotein cholesterol levels in Patients with coronary heart disease (a post hoc analysis of the treating to new targets [TNT] study)
Abstract
High-dose statin therapy has been demonstrated to provide incremental benefit when low-density lipoprotein (LDL) cholesterol concentrations are lowered well below recommended target levels. This secondary analysis of the Treating to New Targets (TNT) study was conducted to investigate whether the attainment of very low LDL cholesterol levels was associated with a further reduction in major cardiovascular events compared with higher LDL cholesterol concentrations and whether any incremental benefit was achieved without additional safety risk. Patients with coronary heart disease and LDL cholesterol levels <130 mg/dl (3.4 mmol/L) were randomized to therapy with atorvastatin 10 mg/day (n = 5,006) or 80 mg/day (n = 4,995). The primary end point was the occurrence of a first major cardiovascular event. Clinical outcomes and safety data were compared across on-treatment LDL cholesterol quintiles. There was a highly significant reduction in the rate of major cardiovascular events with descending achieved levels of on-treatment LDL cholesterol (p <0.0001 for trend across LDL cholesterol). Analysis of individual components of the primary end point demonstrated similar results. Death from any cause and from noncardiovascular causes was lowest in patients with the lowest on-treatment LDL cholesterol levels. Cardiovascular deaths were also reduced with lower levels of on-treatment LDL cholesterol. There were no clinically important differences in adverse event rates across quintiles. Specifically, no increase in muscle complaints, suicide, hemorrhagic stroke, or cancer deaths was observed at the lowest LDL cholesterol levels. In conclusion, the present analysis adds support to the concept that for patients with established atherosclerotic cardiovascular disease, a further risk reduction without sacrifice of safety can be achieved by reducing LDL cholesterol to very low levels.
Similar articles
-
Intensive lipid lowering with atorvastatin in patients with stable coronary disease.N Engl J Med. 2005 Apr 7;352(14):1425-35. doi: 10.1056/NEJMoa050461. Epub 2005 Mar 8. N Engl J Med. 2005. PMID: 15755765 Clinical Trial.
-
Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study.Diabetes Care. 2006 Jun;29(6):1220-6. doi: 10.2337/dc05-2465. Diabetes Care. 2006. PMID: 16731999 Clinical Trial.
-
Effects of high-dose atorvastatin on cerebrovascular events in patients with stable coronary disease in the TNT (treating to new targets) study.J Am Coll Cardiol. 2006 Nov 7;48(9):1793-9. doi: 10.1016/j.jacc.2006.07.041. Epub 2006 Oct 17. J Am Coll Cardiol. 2006. PMID: 17084252 Clinical Trial.
-
Efficacy and safety of intensive statin therapy in the elderly.Am J Geriatr Cardiol. 2008 Mar-Apr;17(2):92-100. Am J Geriatr Cardiol. 2008. PMID: 18326948 Review.
-
Atorvastatin: gold standard for prophylaxis of myocardial ischemia and stroke - comparison of the clinical benefit of statins on the basis of randomized controlled endpoint studies.Eur J Med Res. 2004 Jan 26;9(1):1-17. Eur J Med Res. 2004. PMID: 14766335 Review.
Cited by
-
Role of Lipid-Lowering Therapy in Low-Density Lipoprotein Cholesterol Goal Attainment: Focus on Patients With Acute Coronary Syndrome.J Cardiovasc Pharmacol. 2020 Dec;76(6):658-670. doi: 10.1097/FJC.0000000000000914. J Cardiovasc Pharmacol. 2020. PMID: 33002965 Free PMC article. Review.
-
Total cholesterol and mortality from ischemic heart disease and overall cardiovascular disease in Korean adults.Medicine (Baltimore). 2019 Sep;98(36):e17013. doi: 10.1097/MD.0000000000017013. Medicine (Baltimore). 2019. PMID: 31490384 Free PMC article.
-
Pharmacological interventions for heart failure in people with chronic kidney disease.Cochrane Database Syst Rev. 2020 Feb 27;2(2):CD012466. doi: 10.1002/14651858.CD012466.pub2. Cochrane Database Syst Rev. 2020. PMID: 32103487 Free PMC article.
-
Statins and Cataracts--a visual insight.Curr Atheroscler Rep. 2015;17(2):477. doi: 10.1007/s11883-014-0477-2. Curr Atheroscler Rep. 2015. PMID: 25488134 Review.
-
Reduction in total recurrent cardiovascular events in acute coronary syndrome patients with low-density lipoprotein cholesterol goal <70 mg/dL: a real-life cohort in a developing country.Ther Clin Risk Manag. 2016 Mar 3;12:353-60. doi: 10.2147/TCRM.S96016. eCollection 2016. Ther Clin Risk Manag. 2016. PMID: 27042081 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical